Compare NXRT & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXRT | KMDA |
|---|---|---|
| Founded | 2014 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 469.4M | 460.3M |
| IPO Year | 2014 | 2013 |
| Metric | NXRT | KMDA |
|---|---|---|
| Price | $17.70 | $7.96 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $25.25 | $13.50 |
| AVG Volume (30 Days) | ★ 519.3K | 67.3K |
| Earning Date | 11-03-2026 | 11-09-2026 |
| Dividend Yield | ★ 11.54% | 5.22% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $251,281,000.00 | N/A |
| Revenue This Year | $2.06 | $9.50 |
| Revenue Next Year | $2.37 | $12.63 |
| P/E Ratio | ★ N/A | $24.59 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.67 | $6.55 |
| 52 Week High | $32.36 | $9.35 |
| Indicator | NXRT | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 35.91 | 49.04 |
| Support Level | N/A | $6.94 |
| Resistance Level | $20.22 | $8.05 |
| Average True Range (ATR) | 0.66 | 0.20 |
| MACD | 0.10 | 0.02 |
| Stochastic Oscillator | 8.31 | 75.38 |
NexPoint Residential Trust Inc is a real estate investment trust company. The trust's objectives are to maximize the cash flow and value of properties owned, acquire properties with cash flow growth potential, provide quarterly cash distributions, and achieve long-term capital appreciation for stockholders. It focuses on acquiring multifamily properties in markets with attractive job growth and household formation fundamentals predominantly in the Southeastern and Southwestern United States. The company generates revenue from the rental of multifamily properties.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.